Flavonoids are natural antioxidants found in various foods, and a major source is black tea. Some experimental evidence indicates that flavonoids could prevent prostate cancer. We investigated the associations between flavonoid intake, black tea consumption, and prostate cancer risk in the Netherlands Cohort study, which includes 58,279 men who provided detailed baseline information on several cancer risk factors. From 1986 to 2003, 3,362 prostate cancers were identified, including 1,164 advanced (stage III/IV) cancers. Cox proportional hazards regression using the case-cohort approach was used to estimate hazard ratios and 95% confidence intervals. Intake of total catechin, epicatechin, kaempferol, and myricetin and consumption of black tea were associated with a decreased risk of stage III/IV or stage IV prostate cancer. Hazard ratios of stage III/IV and stage IV prostate cancer for the highest versus the lowest category of black tea consumption (≥5 versus ≤1 cups/day) were 0.75 (95% confidence interval: 0.59, 0.97) and 0.67 (95% confidence interval: 0.50, 0.91), respectively. No associations were observed for overall and nonadvanced prostate cancer. In conclusion, dietary flavonoid intake and black tea consumption were associated with a decreased risk of advanced stage prostate cancer. advanced prostate cancer; black tea; catechins; flavonoids; flavonols; prostate cancer Abbreviations: CI, confidence interval; NLCS, Netherlands Cohort Study; PSA, prostate-specific antigen.
on enzyme activities, anti-inflammatory effects, and inhibition of angiogenesis (9) (10) (11) .
In one small proof-of-principle clinical trial among 60 men with high-grade prostate intra-epithelial neoplasia, the chemopreventive effects of green tea catechins on prostate cancer were investigated (12, 13) . High-grade prostate intraepithelial neoplasia is a likely precursor of prostate cancer (14) . In that double-blind, placebo-controlled study, participants received 3 (200-mg) green tea catechin capsules per day, and after 1 year only 1 tumor was diagnosed among the 30 green tea catechin-treated men, whereas 9 cancers were found among the 30 placebo-treated men.
Unlike the experimental evidence, the few observational studies of flavonoids and prostate cancer conducted to date have reported mostly null results (15) (16) (17) (18) (19) (20) , and observational studies of tea and prostate cancer have been generally inconclusive (5, 21, 22) . It is important to note that most of these studies were limited by a small number of cases and that studies of tea consumption and prostate cancer risk often were limited by a narrow range of tea intake. An additional consideration is that although risk factors for prostate cancer are likely to differ for subgroups that are based on disease stage or aggressiveness (23) , few of these studies considered the clinical or pathological manifestations of prostate cancer in the study design and interpretation.
We therefore investigated the associations between dietary flavonoid intake, black tea consumption, and prostate cancer risk in a large cohort from the Netherlands with a relatively wide range of these exposures. We evaluated intake of total catechin, total flavonol, and specific catechins (catechin and epicatechin) and flavonols (quercetin, kaempferol, and myricetin). We investigated risk of both overall prostate cancer and prostate cancer subgroups that are based on disease stage because associations could be different in these subgroups.
MATERIALS AND METHODS

Study population
The Netherlands Cohort Study (NLCS) is an ongoing prospective cohort study that started in September 1986. The NLCS includes 58,279 men who were 55-69 years of age at baseline. All cohort members completed a baseline questionnaire (24) . Follow-up for incident cancer has been established by record linkage to the Netherlands cancer registries and the Dutch Pathology Registry (25) . The completeness of cancer follow-up through linkage with these registries was assessed to be at least 96% (26) . The NLCS uses a case-cohort approach for data processing and analysis; case subjects were derived from the entire cohort, and the person-time experience was estimated from a subcohort randomly sampled from the full cohort at baseline (27) . The present study is based on a follow-up period of 17.3 years (September 1986-December 2003). In our analysis, we excluded all cases with prevalent cancer other than skin cancer at baseline. We also excluded subjects with incomplete or inconsistent dietary data, according to criteria described previously (28) , and subjects with missing information on tea consumption ( Figure 1 ). Our study included 3,362 incident prostate cancer cases and 2,128 subcohort members. The NLCS has been approved by the institutional review boards of the TNO (Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek (Netherlands Organization for Applied Scientific Research)) Nutrition and Food Research Institute (Zeist, the Netherlands) and Maastricht University (Maastricht, the Netherlands).
Classification of prostate cancer cases
We evaluated prostate cancer subgroups that were based on disease stage. Advanced prostate cancers (International Figure 1 ). Of all advanced prostate cancers, 736 were stage IV prostate cancers ( Figure 1) . A small number of cases had missing data on tumor stage (n = 212) and could not be classified as either advanced or nonadvanced prostate cancers.
Exposure assessment
Dietary intake of study participants was derived from a baseline 150-item semiquantitative food frequency questionnaire that is described in greater detail elsewhere (24, 28, 30) . This dietary assessment was part of a larger questionnaire that also included questions about lifestyle and health. Flavonoid concentrations in foods and beverages were derived from food composition tables that are based on data gathered in the Netherlands (31) (32) (33) (34) . Major flavonoid subgroups in our study were catechins and flavonols. Specific catechins in our study were (+)-catechin and (-)-epicatechin. The catechins (+)-gallocatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epigallocatechin gallate are found almost exclusively in tea and were therefore not evaluated separately. Specific flavonols in our study were quercetin, kaempferol, and myricetin. Flavones are another flavonoid subclass, and the only flavone consumed in our population was luteolin. Because flavones are a minor group of flavonoids compared with the flavonols, the term flavonols will be used here for the sum of both groups. With regard to tea consumption, cohort members were asked whether they drank tea and, if so, how many cups per day. The type of tea was not specified, but this population rarely drank tea other than black tea (35) . On the basis of a pilot study, the standard cup size was assumed to be 125 mL (35) .
Statistical analyses
We used Cox proportional hazards regression to obtain hazard ratios and corresponding 95% confidence intervals for the association between quartiles of flavonoid intake and categories of black tea consumption and risk of prostate cancer and prostate cancer subgroups based on disease stage. Cutoff points for each quartile were based on the distribution of each variable in the subcohort. Tests for linear trend were carried out by taking the median values of all quartiles and modeling intake as a continuous variable. All models were adjusted for age at baseline (in years) as a continuous variable. The following factors, which are hypothesized or known to be associated with prostate cancer, flavonoid intake, or black tea consumption, were assessed as potentially confounding variables: family history of prostate cancer among first-degree relatives (yes or no); smoking status (never, former, or current); duration of smoking (years); frequency of smoking (cigarettes/day); nonoccupational physical activity (≤30, >30-60, >60-90, or >90 minutes/day); body mass index (calculated as weight (in kilograms) divided by height (in meters squared); <23, 23 to <25, 25 to <27, 27 to <30, or ≥30); height (centimeters); diabetes (type I or II, yes/no); educational level ( primary school, lower vocational school, high school, or higher vocational school/university); and intake of energy (kilocalories/day), alcohol (grams/day), calcium (grams/day), lycopene (milligrams/day), vitamin E (milligrams/day), red meat (grams/day), and coffee (cups/day).
We evaluated whether adding any of these variables to the age-adjusted model changed the hazard ratio by at least 10%. Because none did so, our final model was adjusted only for age at baseline. We additionally present our primary findings adjusted for all these potential confounders to show that addition of those factors did not appreciably alter the results.
The proportional hazards assumption was tested by using the scaled Schoenfeld residuals (36) . Standard errors were estimated by using the robust Huber-White sandwich estimator to account foradditional variance introduced bysampling from the cohort (37) .
To examine the influence of preclinical disease on our results, we repeated the analyses with the first 2 years of follow-up excluded. To investigate possible confounding due to differences in prostate-specific antigen (PSA) testing, we stratified by time period to determine whether the observed associations were different in an early period when PSA testing had not yet been introduced in the Netherlands (1986-1994) and a late period when PSA testing was used in clinical practice (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) in the Netherlands. All P values were 2 sided, with a P value less than 0.05 considered to be statistically significant. Analyses were performed in Stata, version 11 (StataCorp LP, College Station, Texas).
RESULTS
The baseline characteristics of our study population are shown in Table 1 . Compared with subcohort members, prostate cancer cases were more likely to have a first-degree relative with prostate cancer and less likely to have a history of diabetes. Important sources of flavonoids in our population were black tea, allium vegetables, apples and pears, cabbages, chocolate, legumes, and leafy vegetables ( Table 2 ). Black tea was by far the major source of total catechin (80%), kaempferol (70%), and myricetin (78%) and contributed significantly to intake of catechin (35%), epicatechin (46%), total flavonol (46%), and quercetin (35%).
We present age-adjusted hazard ratios and 95% confidence intervals. Dietary flavonoid intake was not associated with overall or nonadvanced prostate cancer risk (Table 3) . Intake of total catechin, epicatechin, kaempferol, and myricetin was associated with a decreased risk of advanced (stage III/IV) or stage IV prostate cancer, and hazard ratios of stage IV prostate cancer for the highest versus the lowest quartile of intake of total catechin, epicatechin, kaempferol, and myricetin were, respectively, 0.73 (95% confidence interval (CI): 0.57, 0.95; P for trend = 0.01), 0.74 (95% CI: 0.57, 0.95; P for trend > 0.01), 0.78 (95% CI: 0.61, 1.00; P for trend = 0.03), and 0.71 (95% CI: 0.55, 0.91; P for trend = 0.03).
We investigated associations between black tea consumption and prostate cancer risk. The median consumption of black tea in our population was 2 cups/day. Black tea consumption was inversely associated with risk of advanced (stage III/IV) and stage IV prostate cancer but not with risk of overall and nonadvanced (stage I/II) prostate cancer ( Table 4 ). The hazard ratio of advanced prostate cancer for the highest versus the lowest category of black tea consumption (≥5 versus ≤1 cups/day) was 0.75 (95% CI: 0.59, 0.97; P for trend = 0.04), and the hazard ratio for an increment of 1 cup/day was 0.97 (95% CI: 0.93, 1.01). The hazard ratio of stage IV prostate cancer for the highest versus the lowest category of black tea consumption (≥5 versus ≤1 cups/day) was 0.67 (95% CI: 0.50, 0.91; P for trend = 0.01), and the hazard ratio for an increment of 1 cup/day was 0.95 (95% CI: 0.90, 0.99). These associations were similar when adjusted for all potential confounders (hazard ratio of stage IV prostate cancer for ≥5 versus ≤1 cups/day: 0.67 (95% CI: 0.48, 0.94; P for trend = 0.04)).
Fruits and vegetables contain many antioxidant metabolites other than flavonoids (e.g., vitamin C, lycopene). We studied whether the association between black tea consumption and stage III/IV and stage IV prostate cancer was modified by intake of total fruits and vegetables (less than or equal to median intake, higher than median intake), but it was not (P for interaction > 0.05).
To examine the influence of preclinical disease on our results, we repeated the analyses with the first 2 years of follow-up excluded, and we observed that the results were unchanged (data not shown). To examine whether confounding by PSA testing might explain the associations, we stratified by time period and separately evaluated an early period ( pre-PSA period: 1986-1994) and a late period (PSA period: 1995 (PSA period: -2003 . We observed that the point estimates were comparable in both time periods, and hazard ratios for the association between black tea consumption (≥5 versus ≤1 cups/day) and stage IV prostate cancer risk in the early and late periods were 0.63 (95% CI: 0.41, 0.97; P for trend = 0.02) and 0.69 (95% CI: 0.48, 1.00; P for trend = 0.16), respectively.
DISCUSSION
This large prospective study showed that intake of total catechin, epicatechin, kaempferol, and myricetin and consumption of black tea were associated with a decreased risk of prostate cancer of advanced stage (stage III/IV or stage IV). None of the exposures considered were associated with risk of overall or nonadvanced prostate cancer (stage I/II). The associations were robust in that they remained unchanged after exclusion of cases diagnosed during the first 2 years of follow-up. The hazard ratios were similar after multivariable adjustment, which implies that there was no substantial confounding by any of the additionally included covariables.
Few observational studies have investigated associations between flavonoid intake and prostate cancer risk, and most of these reported null results (15) (16) (17) (18) (19) (20) . None of these studies evaluated prostate cancer subgroups based on tumor characteristics. One small Finnish prospective cohort study, which included 95 prostate cancer cases, previously showed that myricetin intake was inversely associated with overall prostate cancer risk (17) . In our population, black tea was by far the major source of myricetin (78%), but in the Finnish population, information on tea consumption was not available because overall tea consumption was very low. The major source of myricetin in the Finnish population was berries.
A recent meta-analysis of prostate cancer and consumption of black tea (11 studies) and green tea (7 studies) showed that green tea but not black tea might have a protective effect against prostate cancer (21) . Most studies of green tea were conducted in Asian populations. Previous observational studies of black tea consumption and prostate cancer reported mostly null results (5, 21) , but interestingly, the pathological manifestations of prostate cancer were considered in only 2 small-scale studies. In one population-based case-control study (87 aggressive prostate cancers) (38) and one prospective cohort study (70 prostate cancers with a Gleason score ≥8) (22) , no association was observed between black tea consumption and risk of aggressive prostate cancer.
In one prospective cohort study in Japan, it was shown that consumption of green tea was inversely associated with risk of advanced prostate cancer but not with overall or localized prostate cancer (39) . That study included 404 incident prostate cancers, of which 114 were advanced cancers. The multivariable adjusted relative risk for advanced prostate cancer for the highest versus the lowest category of green tea consumption (≥5 versus <1 cups/day) was 0.52 (95% CI: 0.28, 0.96; P for trend = 0.01). This association was stronger than the association between black tea consumption and advanced prostate cancer risk in our study, and one possible explanation for this is the higher concentration of catechins in green tea than in black tea (7) . Tea polyphenols are absorbed mainly from the small intestine and are then subject to phase II metabolism, which likely affects their bioavailability (7) . In a human preprostatectomy trial, however, it was shown that black and green tea polyphenols are bioavailable in the prostate (40) . Flavonoids have various biological properties by which an association with a decreased risk of advanced stage prostate cancer could be explained. The most widely recognized biological properties of flavonoids are the antioxidant properties (2, 41) , and oxidative stress is believed to be related to prostate carcinogenesis (42, 43) . Various antioxidants have been associated with advanced stage prostate cancer (7, 44) . In addition, flavonoids can affect apoptosis, angiogenesis, and inflammatory processes, all of which play roles in prostate cancer progression (6) (7) (8) (9) (10) (11) .
Black tea contains a high concentration of theaflavins and thearubigins, which are polymeric polyphenols. These compounds are formed from catechins during fermentation of tea leaves and might also have anticarcinogenic activity. In studies using cell lines, theaflavin and thearubigin inhibited prostate cancer growth (45, 46) . Nevertheless, because of the limited bioavailability of these compounds, it is believed that they generally do not contribute to the chemopreventive effects of black tea in vivo (7) .
In our study, we did not obtain information on infusion time of tea or tea strength. Such additional information could have provided us with a more precise estimation of daily flavonoid intake. Another possible limitation is that misclassification could have occurred in the assignment of flavonoid levels to the foods reported. Although the NLCS food frequency questionnaire has been shown to be valid and reproducible (28, 30) , there are no separate validation data on flavonoids. Flavonoid concentrations are known to vary greatly by food variety, and thus, individual preferences for particular varieties of foods would lead to misclassification. Our analyses were performed with baseline food frequency questionnaire data, and it is therefore possible that changes in black tea consumption after 1986 resulted in attenuation of our risk estimates. Inaccuracy of recall of tea consumption as such also could be a source of bias. Unfortunately, we had no separate data on tea available from the validation study of our food frequency questionnaire (28) , but considering the simplicity of the question on tea and the small number of blanks encountered, we would expect that the accuracy of recall was even better than average. Another limitation is that we had no information on PSA testing, which might be a confounder. We nonetheless showed that the observed associations were similar in an early period when PSA testing was not yet introduced in the Netherlands (1986-1994) and a late period when PSA testing was used in clinical practice in the Netherlands (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) . It is also important to note that PSA testing was introduced relatively slowly in the Netherlands compared with other high-income countries, and it has never been used for systematic screening or case finding (47). In 2001, only 14% of men more than 45 years of age in the Netherlands had had a PSA measurement in the previous 5 years (47) . On the basis of this evidence, it is unlikely that PSA testing is an explanation for the observed associations in our study. Our study has several strengths, including its prospective design, large sample size, and long and nearly complete follow-up. The range of black tea intake in our cohort was wide. We had data on tumor stage for most cases, which made it possible to stratify by disease stage, and our study included a large number of advanced stage prostate cancers. Our food frequency questionnaire contained questions about all important sources of flavonoids, and we have data on many potential confounding variables.
In conclusion, men with a high intake of black tea, total catechin, epicatechin, kaempferol,andmyricetin hadareduced risk of prostate cancer of advanced stage. These findings need to be reproduced in other large-scale observational studies with comprehensive data on flavonoid concentrations in foods and beverages and evaluation of prostate cancer subgroups on the basis of pathological manifestations.
